Rectovaginal Fistula Clinical Trial
Official title:
Evaluation of Effectiveness and Safety of Autologous Adipose-derived Regenerative Cells Injection for Treatment of Radiation-induced Rectovaginal Fistula
Verified date | January 2020 |
Source | South Ural State Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A new strategy for treatment of late radiation damage is to develop methods aimed at
stimulating the regenerative capabilities of irradiated tissues. Since the main pathogenetic
mechanism of the development of late radiation damage is the death or damage of the
replicative mechanism of stromal cells (SC), a justified approach can be considered as
transplantation of intact SC. Currently, there is convincing evidence in the scientific
literature that the injection of intact autologous SCs into the zone of fibrosis surrounding
the chronic radiation ulcer leads to the healing of a wound defect.
An Initiative Clinical Trial. Introduction of autologous regenerative cells of adipose tissue
for the treatment of post-irradiation vaginal-rectal fistula. It is assumed that patients
will be included in the project within 12 months; the monitoring of each patient will last
for 6 months; the total duration of the clinical part of the study will be 18 months; The
total duration of the clinical trial including the preparatory phase and the writing of the
report is about 24 months. It is assumed that at least 16 patients aged 20 to 75 years who
have verified diagnosis of post-irradiation vaginal-rectal fistula will participate in this
pilot project. The aims of the clinical trial are to preliminarily assess the safety,
effectiveness and quality of life of patients after introducing autologous regenerative cells
of adipose tissue for the treatment of post-irradiation vaginal-rectal fistula.
Status | Completed |
Enrollment | 16 |
Est. completion date | January 22, 2020 |
Est. primary completion date | November 15, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of radiation-induced rectovaginal fistula established at least six months after radiation therapy - Absence of oncological disease relapse during whole observation period - Absence of rectal and anal cancer - Patient have read and signed informed consent Exclusion Criteria: - Contraindications for local/general anesthesia or a history of anesthetic medicines allergy - Acute hemorrhoid or anal fissure - Acute purulent paraproctitis - Inflammatory colon diseases - History of extensive posttraumatic or postoperative alterations which causes obstacles to follow protocol examination - Chronic sub- or decompensated internal organs diseases - Clinically significant laboratory tests abnormalities - Conditions that limits patient compliance (dementia, psycho-neurological diseases, drug abuse, alcohol abuse etc.) - Patients involved in other clinical trials or taking medications under research during last three months - Cancer patients including postoperative chemo- or/and radiotherapy at least three months after surgery - Patients with increased activated partial thromboplastin time level 1,8 times above normal - Patients who take anticoagulants or took anticoagulants at least one month before including into trial - Patients who take or took before investigation glycoprotein inhibitors IIB/IIIA - Patients with history of taking medications that influence fatty tissue structure |
Country | Name | City | State |
---|---|---|---|
Russian Federation | South Ural State Medical University | Chelyabinsk | Chelyabinsk Oblast |
Lead Sponsor | Collaborator |
---|---|
South Ural State Medical University |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serious adverse events | Frequency, type and severity of serious adverse events (SAE) | 4 weeks after injection of adipose-derived regenerative cells | |
Primary | Serious adverse reactions | Frequency, type and severity of serious adverse reactions (SAR) | 4 weeks after injection of adipose-derived regenerative cells | |
Secondary | Changes of fistula size | Intervention impact on dimensions of rectovaginal fistula | 48 weeks after intervention | |
Secondary | Changes in rectovaginal soft tissue density and flexibility | Intervention impact on soft tissue density and flexibility assessed by ultrasound elastography | 48 weeks after intervention | |
Secondary | Quality of life monitoring - 1 | Quality of life estimated by validated questionnaire: The Short Form (36) Health Survey (SF-36). SF-36 is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The eight sections are: vitality physical functioning bodily pain general health perceptions physical role functioning emotional role functioning social role functioning mental health |
48 weeks after intervention | |
Secondary | Quality of life monitoring - 2 | Quality of life estimated by validated questionnaire. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C-30 with module for proctitis-23 is a questionnaire developed to assess the proctitis-specific quality of life of cancer patients. Each subscale values varies from 1 to 4. Lower values represents better life quality. Total score is computed by summarizing of subscales. | 48 weeks after intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00999115 -
Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn`s Disease (ALOREVA)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04519697 -
Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05709717 -
Regenerative Therapy With Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cells and Platelet-rich Plasma to Treat Complex Perianal Diseases
|
||
Completed |
NCT05079139 -
Musset's Surgical Technique: Evaluation of Long-term Results (LONGOMUSSET)
|
N/A | |
Active, not recruiting |
NCT04940611 -
A Study of Surgical Interventions in Fistulizing Conditions
|